Fig. 3From: In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinibEffect of ABCB1 overexpression on bosutinib activity. a Proliferation assay on K562DOX, K562DOX/sh P-GP, and K562S. Cells were cultivated for 72 h in the presence of increasing concentration of either bosutinib or imatinib, and incorporation of tritiated thymidine was evaluated. Results presented are an average of at least three independent experiments. b Proliferation assay of K562DOX and K562S cells co-treated with verapamil and either bosutinib or imatinib. Verapamil was used at three selected concentrations, while bosutinib and imatinib were used within the same ranges used in Fig. 3a. The y axis reports means + SD of bosutinib or imatinib IC50s obtained. Data reported are a mean of three separate experiments. Non-linear regression was used to evaluate IC50s. c Evaluation of BCR-ABL phosphorylation levels in K562DOX and K562S cell lines, upon bosutinib treatment with or without verapamil co-treatment. Immunoblotting analysis was performed on whole cell lysates. ABL1 was used as a loading controlBack to article page